Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
| Status: | Completed |
|---|---|
| Conditions: | Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 10/21/2018 |
| Start Date: | January 2007 |
| End Date: | July 2010 |
A Phase 1 Dose-Escalation Study to Examine the Safety and Tolerability of IC83/LY2603618 Administered After Pemetrexed 500 mg/m2 Every 21 Days in Patients With Cancer
The purpose of this study is to evaluate the safety and tolerability of IC83/LY2603618 for
the treatment of cancer.
the treatment of cancer.
Inclusion Criteria:
- Has at least one lesion that can be evaluated by Response Evaluation Criteria In Solid
Tumors (RECIST)
- Has fully recovered from all toxicities due to the following:
1. Local radiation therapy that ended at least 14 days prior to Cycle 1, Day 1.
2. Surgery.
- Has a life expectancy of at least 3 months.
- Negative serum pregnancy test.
Exclusion Criteria:
- Is pregnant or breastfeeding.
- Is a woman of childbearing potential unwilling to use an approved, effective means of
contraception according to the institution's standards.
- Is a man of childbearing potential unwilling to use an approved, effective means of
contraception according to the institution's standards.
- Has a history of brain metastases, unless adequately treated and without radiologic
evidence of progressive disease for at least 3 months after completion of therapy.
- Has a known active infection.
We found this trial at
1
site
Click here to add this to my saved trials
